Nuage-therapeutics

Discovery engine for small molecule modulators of disordered targets

Our science

Nuage Therapeutics mission is to leverage chemical biology and biomolecular condensation to develop selective drugs targeting proteins with disordered regions for challenging indications to improve patient’s life

Our team

Xavier Salvatella

Xavier Salvatella

Founder

Mateusz Biesaga

Mateusz Biesaga

Founder

Denes Hnisz

Denes Hnisz

Founder

Judit Anido

Judit Anido

Founder & CEO

Pilar Casado

Pilar Casado

Chief Financial Officer

Jordina Guillén

Jordina Guillén

Head of Science

Andri Leonidou

Andri Leonidou

Head of BI & Corp. Affairs

Alessandra Bartolozzi

Alessandra Bartolozzi

Head of Medicinal Chemistry

Board of Directors

Clara Campàs

Clara Campàs

Board member

Xavier Salvatella

Xavier Salvatella

Board member

Maina Bhaman

Maina Bhaman

Board member

Judit Anido

Judit Anido

Board member

Nuage Therapeutics scientific founders publish new research in Nature Structural & Molecular Biology

December 4, 2023

Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys

June 21, 2023

Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO

May 10, 2022

Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA is launched with the support of Asabys

September 28, 2021

Private investors:

This company is invested by Innvierte, an investment program of CDTI, E.P.E.

Project grants:

  • Nuage Therapeutics has been awarded with the CDTI grant SNEO-2022214, in collaboration with Ministerio de Ciencia e Innovación and cofunded by the European Union–Next Generation EU
  • Grant PTQ2021-011994 and PTQ2021-011961 awarded by MCIN/AEI/10.13039/501100011033

Careers

Job opening for Business Development Manager at Nuage Therapeutics

view details

Job opening for Scientist (assay development) at Nuage Therapeutics

view details

Get in touch

Address:
Parc Científic de Barcelona 
c/ Baldiri Reixac 4-8 (Torre I)
08028 Barcelona

10 + 8 =